DUBLIN–(BUSINESS WIRE)–The “Global
HDAC (histone deacetylase) Inhibitors Market 2019-2023” report
has been added to ResearchAndMarkets.com’s offering.
The HDAC (histone deacetylase) inhibitors market will register a CAGR of
nearly 7% by 2023.
The development of novel drug delivery systems and combination therapies
will drive the HDAC inhibitors market growth during the forecast period.
Chemotherapeutic drugs are increasingly being administered orally or
intravenously for treating different tumors.
However, there are instances that these active pharmaceutical
ingredients often do not reach the targeted site in appropriate
quantities, eventually, lowering the performance of the drugs. As a
result, with the rising shift of research and prescription toward
combination therapies using HDAC inhibitors, the market is expected to
witness considerable growth during the forthcoming years.
High prevalence of oncology indications
One of the growth drivers of the global HDAC (histone deacetylase)
inhibitors market is the high prevalence of oncology indications. The
high growth in various types of cancers and neurologic conditions,
coupled with high unmet need in the treatment landscape of these
diseases will drive the growth of the market.
High costs associated with treatment
One of the challenges in the growth of the global HDAC (histone
deacetylase) inhibitors market is the high costs associated with
treatment. The high treatment costs act as a barrier for drug adoption,
which reduces the patient base and poses a challenge to market growth.
The market appears to be moderately concentrated with the presence of a
few market players. Companies are focusing on research on several other
types of cancers using HDAC inhibitors due to their high target affinity
and specificity. This market research report will help clients identify
new growth opportunities and design unique growth strategies by
providing a comprehensive analysis of the market’s competitive landscape
and offering information on the products offered by companies.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: MARKET SEGMENTATION BY ROA
- Market segmentation by RoA
- Comparison by RoA
- Oral HDAC inhibitors – Market size and forecast 2018-2023
- Parenteral HDAC inhibitors – Market size and forecast 2018-2023
- Market opportunity by RoA
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2018-2023
- Europe – Market size and forecast 2018-2023
- Asia – Market size and forecast 2018-2023
- ROW – Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Celgene Corp
- Merck & Co., Inc.
- Novartis AG
- Shenzhen Chipscreen Biosciences Co., Ltd.
- Spectrum Pharmaceuticals, Inc.
PART 14: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/s99qgt
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Nervous System Drugs, Enzymes